He joins the firm with more than 15 years of vaccine research and development experience and leadership roles
Novavax, a clinical-stage vaccine company focused on the development of recombinant nanoparticle vaccines and adjuvants, has appointed Jeffrey Stoddard as Vice President, Medical Affairs.
Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis, FluMist, pandemic flu vaccines, Menveo and Bexsero. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes, where he led medical affairs, and health economics and outcomes research.
Prior to this, Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune.